 |
||||
| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
|
||||
| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
REGULAR ARTICLES |
*
Department of Endocrinology, Diabetes and Internal Medicine, Division of
Medicine, King's College London Guy's Hospital, London, United
Kingdom
Renal Pathology Unit GKT School of Medicine, King's College London Guy's
Hospital, London, United Kingdom.
Correspondence to Dr. Stephen Thomas, Department of Diabetes, Endocrinology and Internal Medicine, GKT School of Medicine KCL, 5th Floor, Thomas Guy House, Guy's Hospital, London SE1 9RT, United Kingdom. Phone : +44 0171 955 4826 ; Fax : +44 0171 955 2985 ; E-mail : stephen.thomas{at}kcl.ac.uk
Abstract. Mesangial cell proliferation and growth factor over-expression are characteristic features of several glomerular diseases. Vascular endothelial growth factor (VEGF), a potent mitogen, is expressed in podocytes in the glomerulus, and VEGF receptors (flt-1, KDR, and neuropilin-1) are present on endothelial cells and other cell types. This study examined whether human mesangial cells (HMC) express VEGF receptors in vitro and ex vivo and evaluated the effect of VEGF on HMC proliferation. All receptor types were detected in HMC in vitro by immunofluorescence and Western blotting. VEGF165 induced a dose-responsive increase in 3H-thymidine incorporation (25 ng/ml VEGF165 : 2.3-fold increase ; 50 ng/ml : 3.8-fold ; 100 ng/ml : 4.8-fold ; 200 ng/ml : 3.4-fold ; P = 0.016) and in cell number (50 ng/ml VEGF165 : 1.2-fold increase ; 100 ng/ml : 1.6-fold ; 200 ng/ml : 1.4-fold ; P = 0.005), effects prevented by an anti-VEGF165 polyclonal neutralizing antibody (100 µg/ml). The proliferative effect was confirmed by a tetrazolium dye-based assay (100 ng/ml VEGF165 : 1.4-fold increase). In ex vivo experiments, VEGF receptors in biopsy material from normal and diseased kidneys were detected by immunohistochemistry. No mesangial flt-1 receptor staining was seen in normal renal cortical tissue samples, and only weak mesangial KDR staining was detected. In contrast, mesangial flt-1 and KDR receptor staining were both clearly seen in biopsy samples from proliferative renal diseases. In conclusion, flt-1, KDR, and neuropilin-1 are present on cultured HMC, and VEGF165 induces HMC proliferation. In addition, the flt-1 and KDR receptors are expressed in the mesangium in mesangioproliferative disease.
This article has been cited by other articles:
 |
|
 |
|
  C.-H. Ku, K. E. White, A. Dei Cas, A. Hayward, Z. Webster, R. Bilous, S. Marshall, G. Viberti, and L. Gnudi Inducible Overexpression of sFlt-1 in Podocytes Ameliorates Glomerulopathy in Diabetic Mice Diabetes, October 1, 2008; 57(10): 2824 - 2833. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Liu, M. Morimoto, S. Kitajima, T. Koike, Y. Yu, H. Shiiki, M. Nagata, T. Watanabe, and J. Fan Increased Expression of Vascular Endothelial Growth Factor in Kidney Leads to Progressive Impairment of Glomerular Functions J. Am. Soc. Nephrol., July 1, 2007; 18(7): 2094 - 2104. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Giunti, D. Barit, and M. E. Cooper Mechanisms of Diabetic Nephropathy: Role of Hypertension Hypertension, October 1, 2006; 48(4): 519 - 526. [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Buhimschi, L. Magloire, E. Funai, E. R. Norwitz, E. Kuczynski, R. Martin, S. Richman, S. Guller, C. J. Lockwood, and I. A. Buhimschi Fractional excretion of angiogenic factors in women with severe preeclampsia. Obstet. Gynecol., May 1, 2006; 107(5): 1103 - 1113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Ellis The role of neuropilins in cancer Mol. Cancer Ther., May 1, 2006; 5(5): 1099 - 1107. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Eremina, S. Cui, H. Gerber, N. Ferrara, J. Haigh, A. Nagy, M. Ema, J. Rossant, S. Jothy, J. H. Miner, et al. Vascular Endothelial Growth Factor A Signaling in the Podocyte-Endothelial Compartment Is Required for Mesangial Cell Migration and Survival J. Am. Soc. Nephrol., March 1, 2006; 17(3): 724 - 735. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H. J. Salmon, C. R. Neal, D. O. Bates, and S. J. Harper Vascular endothelial growth factor increases the ultrafiltration coefficient in isolated intact Wistar rat glomeruli J. Physiol., January 1, 2006; 570(1): 141 - 156. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. R. Foster, M. A. Saleem, P. W. Mathieson, D. O. Bates, and S. J. Harper Vascular endothelial growth factor and nephrin interact and reduce apoptosis in human podocytes Am J Physiol Renal Physiol, January 1, 2005; 288(1): F48 - F57. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. F. Schrijvers, A. S. De Vriese, and A. Flyvbjerg From Hyperglycemia to Diabetic Kidney Disease: The Role of Metabolic, Hemodynamic, Intracellular Factors and Growth Factors/Cytokines Endocr. Rev., December 1, 2004; 25(6): 971 - 1010. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ostendorf, C. van Roeyen, R. Westenfeld, A. Gawlik, M. Kitahara, E. de Heer, D. Kerjaschki, J. Floege, and M. Ketteler Inducible Nitric Oxide Synthase-Derived Nitric Oxide Promotes Glomerular Angiogenesis via Upregulation of Vascular Endothelial Growth Factor Receptors J. Am. Soc. Nephrol., September 1, 2004; 15(9): 2307 - 2319. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Wang, J. H. Kwak, S. I. Kim, Y. He, and M. E. Choi Transforming Growth Factor-{beta}1 Stimulates Vascular Endothelial Growth Factor 164 via Mitogen-activated Protein Kinase Kinase 3-p38{alpha} and p38{delta} Mitogen-activated Protein Kinase-dependent Pathway in Murine Mesangial Cells J. Biol. Chem., August 6, 2004; 279(32): 33213 - 33219. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Mattot, L. Moons, F. Lupu, D. Chernavvsky, R. A. Gomez, D. Collen, and P. Carmeliet Loss of the VEGF164 and VEGF188 Isoforms Impairs Postnatal Glomerular Angiogenesis and Renal Arteriogenesis in Mice J. Am. Soc. Nephrol., June 1, 2002; 13(6): 1548 - 1560. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Banas, M. Wornle, T. Berger, P. J. Nelson, C. D. Cohen, M. Kretzler, J. Pfirstinger, M. Mack, M. Lipp, H.-J. Grone, et al. Roles of SLC/CCL21 and CCR7 in Human Kidney for Mesangial Proliferation, Migration, Apoptosis, and Tissue Homeostasis J. Immunol., May 1, 2002; 168(9): 4301 - 4307. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D.-H. Kang, J. Kanellis, C. Hugo, L. Truong, S. Anderson, D. Kerjaschki, G. F. Schreiner, and R. J. Johnson Role of the Microvascular Endothelium in Progressive Renal Disease J. Am. Soc. Nephrol., March 1, 2002; 13(3): 806 - 816. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Yasukawa, M. Terai, S. T. Shulman, T. Toyozaki, S. Yajima, Y. Kohno, and A. H. Rowley Systemic Production of Vascular Endothelial Growth Factor and fms-Like Tyrosine Kinase-1 Receptor in Acute Kawasaki Disease Circulation, February 12, 2002; 105(6): 766 - 769. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D.-H. KANG, J. HUGHES, M. MAZZALI, G. F. SCHREINER, and R. J. JOHNSON Impaired Angiogenesis in the Remnant Kidney Model: II. Vascular Endothelial Growth Factor Administration Reduces Renal Fibrosis and Stabilizes Renal Function J. Am. Soc. Nephrol., July 1, 2001; 12(7): 1448 - 1457. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Clauss, C. Sunderkotter, B. Sveinbjornsson, S. Hippenstiel, A. Willuweit, M. Marino, E. Haas, R. Seljelid, P. Scheurich, N. Suttorp, et al. A permissive role for tumor necrosis factor in vascular endothelial growth factor-induced vascular permeability Blood, March 1, 2001; 97(5): 1321 - 1329. [Abstract] [Full Text] [PDF]
|
|
|
HOME
CURRENT ISSUE
ARCHIVES
JASN Express
ONLINE SUBMISSION
AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP |
Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673
